KRTX News and Press, Karuna Therapeutics Inc. From 11/10/20

Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced that senior manag...

Karuna Therapeutics (KRTX): Q3 GAAP EPS of -$0.71 beats by $0.07.Cash, cash equivalents and investments of $344.9MPress Release For further details see: Karuna Therapeutics EPS beats by $0.07

On track to initiate first Phase 3 trial within the EMERGENT program by the end of 2020 Topline data from Phase 1b trial in healthy elderly volunteers expected early in the second quarter of 2021 $344.9 million in cash, cash equivalents and investment securities expect...

Today, we provide an in-depth look at a promising biotech named Karuna Therapeutics. The company is well-funded, has an evolving pipeline and has strong analyst support. An investment analysis follows in the paragraphs below. For further details see: Digging Deeper Into ...

The following slide deck was published by Karuna Therapeutics, Inc. in conjunction with this Read more ...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced the appointment of Laur...

Karuna Therapeutics (NASDAQ: KRTX ) : Q2 GAAP EPS of -$0.65 misses by $0.20 . More news on: Karuna Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

  On track to initiate Phase 3 trials within the EMERGENT program, the clinical program evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia, by the end of 2020 Topline data from Phase 1b trial in healthy elderly volunteers expected by the end of 20...

Karuna Therapeutics (NASDAQ: KRTX )   -7%  post market, after  topline results from Phase 1b (KAR-020)  trial of KarXT on experimentally induced pain, were inconclusive and do not provide sufficient evidence of an analgesic benefit of KarXT compared to placebo. More n...

Topline results of exploratory trial do not provide conclusive evidence of an analgesic benefit of KarXT on experimentally induced pain in healthy volunteers The Company will not move forward to evaluate KarXT for the treatment of pain The safety and tolerability profile of KarXT ...